Get our latest issue now

available for iOS, Android & web

latest issue

FDA OK for Taro's psoriasis spray

Daily News | April 15, 2013

Selina McKee

FDA OK for Taro's psoriasis spray

US regulators have issued a green light for Taro Pharmaceutical Industries' corticosteroid psoriasis spray.

The group said that the US Food and Drug Administration has approved its application to market Topicort (desoximetasone) Topical Spray for the treatment of plaque psoriasis in patients 18 years of age or older.

Psoriasis is the most prevalent autoimmune disease in the US, affecting as many as 7.5 million - or 2.2% - of the population.  

Taro, citing "industry sources", noted that the corticosteroid spray market in the US is worth around $100 million a year.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!